Head-to-head · WeighScore
Medro vs PauseRX
By GLP-1 ScorecardUpdated
Score comparison
PauseRX has the higher recorded score — 68.5/100 to 63.6/100.
PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX advertises no membership fee and separate starting prices for its compounded programs. Check the supply, next charge and order cutoff for your plan.
Before you choose
Before comparing the headline prices, the Medro review and the PauseRX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Medro vs Revel RX and No BS RX vs PauseRX compare each of them with another graded program, and the list of alternatives to Medro ranks the programs closest to Medro on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Lttl review covers one graded close to these two, at 63.5/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Medro | PauseRX |
|---|---|---|
| WeighScore | 63.6/100 | 68.5/100 |
| Grade | C | C |
| Site position | #271 | #162 |
| Semaglutide | From $99/mo equivalent (introductory, quarterly prepay, compounded) | Compounded GLP-1 from $199; confirm selected supply and charge |
| Tirzepatide | From $199/mo equivalent (introductory, quarterly prepay, compounded) | Compounded GLP-1/GIP from $249; confirm selected supply and charge |
| Coverage | All 50 states | Confirm availability for the selected product and state |
| Brand-name access | Not confirmed | Yes |
| Oral / sublingual | Not confirmed | Yes |
Strengths
- Names its clinical group
- Publishes a subscription cancellation deadline
What to consider
- Advertised introductory rates require three months paid upfront
- Ask for the regular renewal charge and the refund terms for your order
Strengths
- Publishes starting prices for its two compounded programs
- Lists brand-name options separately
- Publishes a prescription final-sale policy
What to consider
- Starting prices do not establish the full debit or refill charge
- The returns policy makes charged orders final after carrier handoff
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.